Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (NYSE: BDX) has announced it will host an audio webcast on February 6, 2025, at 8 a.m. ET to discuss its first quarter fiscal 2025 financial results for the period ending December 31, 2024. During the webcast, management will present the quarterly results and provide updates on company operations and strategy.
The company will release financial summary materials and a news release prior to the webcast. Investors can access the webcast through BD's investor relations website, where a replay will also be available afterward.
BD (NYSE: BDX) announced major investments in its U.S. manufacturing capabilities for critical medical devices. The company invested over $10 million in 2024 to expand production capacity, adding new needle and syringe lines in Connecticut and Nebraska facilities. This expansion will increase domestic production of safety-engineered injection devices by >40% and conventional syringes by >50%, adding hundreds of millions of units annually.
The company hired 215 full-time employees to support increased production. Additionally, BD plans to invest over $30 million in 2025 to expand IV line manufacturing capacity at its Utah plant, following a $2 million investment in 2024 that increased IV catheter output by >40 million units annually.
BD operates more than 30 manufacturing and distribution facilities across 17 U.S. states and Puerto Rico, employing over 10,000 people. Key facilities include Nebraska (opened 1949), Connecticut (1961), and Utah (1956), which collectively represent 200 years of manufacturing experience.
BD (NYSE: BDX) announced the inclusion of its BD Onclarity™ HPV Assay in the ASCCP Enduring Risk-Based Management Guidelines, marking a significant advancement in cervical cancer screening. The assay stands out for its ability to individually identify six of the 14 cancer-causing HPV types and group the remaining seven into three pooled results, offering more precise risk assessment than traditional tests that typically identify only two types.
The new guidelines support self-collection methods for cervical cancer screening, which is available with the BD Onclarity™ HPV assay in healthcare settings. This feature aims to improve access for those facing barriers to traditional screening methods. The guidelines acknowledge that extended genotyping provides better risk stratification and that repeated detection of the same HPV type indicates higher risk of cervical pre-cancer.
BD (NYSE: BDX) has appointed Pamela Spikner as senior vice president, chief accounting officer and controller, effective January 20. Reporting to CFO Chris DelOrefice, Spikner will oversee all accounting policy and financial reporting for the company.
Spikner brings over 25 years of experience in corporate finance and accounting. She joins BD from R1 RCM, Inc., where she served as chief accounting officer since July 2021, managing financial reporting, compliance, and strategic financial planning. Her previous roles include accounting leadership positions at Exelon for 12 years and assistant corporate controller at Hill-Rom Holdings. She started her career at PwC in the audit practice focusing on healthcare and insurance industries.
A certified public accountant (CPA) and certified internal auditor (CIA), Spikner holds a Bachelor of Science in Accounting from Indiana University of Pennsylvania.
BD (NYSE: BDX) has released a concerning survey about women's gynecological health practices. The Harris Poll survey, conducted in November 2024 among 1,100+ U.S. women, revealed that 72% have delayed gynecology visits, with 54% citing fear or discomfort and 49% mentioning scheduling challenges.
Key findings include: 50% of women are uncertain about cervical cancer screening frequency; 81% desire more comfortable testing options; and 73% show interest in self-collection methods at doctor's offices. Despite 66% claiming knowledge about HPV, 88% are unaware that Pap tests aren't the most accurate for detecting cervical cancer.
The company's BD Onclarity™ HPV Assay, FDA-approved for self-collection, identifies more high-risk HPV types than other tests. Major health organizations, including WHO and ACS, now recommend self-collection for HPV screening. WHO aims to eliminate cervical cancer as a public health issue by 2030, noting it's currently the fourth most common cancer in women worldwide.
BD (NYSE: BDX), a leading global medical technology company, has announced its upcoming 2025 Annual Meeting of Shareholders, which will be held virtually on Tuesday, January 28, 2025, at 1:00 p.m. (ET).
Shareholders of record as of December 9, 2024, or their authorized proxies, will have full participation rights, including the ability to attend, vote, and ask questions during the meeting by accessing the provided virtual platform at https://meetnow.global/M5X7D4A. Guests can also attend in listen-only mode without requiring a control number.
The company will make a replay of the webcast available on the BD website at investors.bd.com for approximately one year following the Annual Meeting.
BD (NYSE: BDX) and Babson Diagnostics announced an expansion of their fingertip blood collection and testing technologies for U.S. health systems and provider networks. The innovation combines BD's MiniDraw™ Capillary Blood Collection System with Babson's BetterWay technologies, requiring only six drops of blood from a finger prick. The system can be operated by any trained healthcare worker without phlebotomy experience.
This development aims to improve access to blood testing in underserved locations and reduce barriers like needle fear and logistical challenges. The partnership, which began in 2016, has already implemented BetterWay blood testing in retail settings since May 2024 and is now expanding to ambulatory care sites across the United States.
BD (BDX) has reached a settlement with the SEC regarding an investigation into previous disclosures about the BD Alaris™ System, acquired from CareFusion in 2015. The company will pay $175 million to resolve the matter, an amount already reserved and disclosed in their FY2024 Form 10-K. The settlement, which involves events from over four years ago, requires no financial restatements and won't affect BD's innovation investments or capital allocation strategy.
The company maintains that the BD Alaris™ System is safe and effective, noting its critical role in healthcare delivery, including during the COVID-19 pandemic. The system received FDA 510(k) clearance in July 2023. BD has implemented improvements to its operational and governance processes, affirming its commitment to ethical standards and product quality.
Vantage Point Logistics (VPL) has appointed Mark Longley as its new Chief Executive Officer, while Co-Founder Eric McGlade transitions to Chairman of the Board. Longley, with over 20 years of healthcare technology experience, joins VPL from Parata Systems, where he served as Chief Commercial Officer and General Manager. At Parata, he led sales, marketing, and strategy operations, playing a important role in the company's successful sale to Becton, Dickinson and Company (BDX). VPL, a clinical supply chain technology company, has experienced rapid growth and established itself as a trusted partner in integrating technology with freight management and pharmacy workflows.
A groundbreaking HPV self-collection screening pilot program has launched in Texas to improve cervical cancer screening in underserved communities. The study, conducted at Su Clinica in partnership with MD Anderson Cancer Center, utilizes the BD Onclarity™ HPV Assay (NYSE: BDX), recently FDA-approved for HPV self-collection screening. The initiative, supported by a $2.5 million CPRIT grant, aims to evaluate implementation effectiveness and develop scalable best practices for nationwide application. The program specifically targets communities facing healthcare barriers, offering bilingual options and financial support for uninsured patients.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
